The study, conducted across multiple research centres, shows that semaglutide not only aids in weight reduction but also improves metabolic markers such as blood sugar and cholesterol levels
The Food and Drug Administration has approved Ozempic for one primary purpose: to improve glycemic control in adults with Type 2 diabetes, with a secondary benefit of reducing the risk of major cardiovascular events in those same adults
National Institute For Health And Care Excellence: Semaglutide for managing overweight and obesity PubMed: Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States Business Insider: How weight-loss injections like Ozempic, Mounjaro, and triple G compare in cost, results, and effectiveness FDA Label: OZEMPIC (Semaglutide Injection) Medication Guide FDA Label: WEGOVY (Semaglutide Injection) Medication Guide FDA Label: RYBELSUS (Oral Semaglutide) Medication Guide FDA Label: MOUNJARO (Tirzepatide Injection) Medication Guide FDA Label: ZEPBOUND (Tirzepatide Injection) Medication Guide Important Medical Information and Disclaimers MEDICAL DISCLAIMER This information is for educational purposes only and is not intended as medical advice, diagnosis, or treatment recommendation
First study author Michael Corley, PhD, associate professor of medicine in the Division of Geriatrics, Gerontology & Palliative Care at UC San Diego School of Medicine and the Stein Institute for Research on Aging, spoke to Medical News Today about the study findings
